Patents by Inventor Tobias Weismueller

Tobias Weismueller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for treatment of autoimmune hepatitis
    Patent number: 10641780
    Abstract: The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: May 5, 2020
    Assignees: The Governors of the University of Alberta, Medizinische Hochschule Hannover
    Inventors: Abdolamir Landi, Michael Houghton, D. Lorne Tyrrell, Tim Lankisch, Tobias Weismueller, Michael Manns
  • Methods and Compositions for Diagnosis of Inflammatory Liver Disease
    Publication number: 20180209992
    Abstract: The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
    Type: Application
    Filed: March 15, 2018
    Publication date: July 26, 2018
    Inventors: Abdolamir Landi, Michael Houghton, D. Lorne Tyrrell, Tim Lankisch, Tobias Weismueller, Michael Manns
  • Methods of treatment of primary sclerosing cholangitis
    Patent number: 9952226
    Abstract: The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: April 24, 2018
    Assignees: Medizinische Hochschule Hannover, The Governors of the University of Alberta
    Inventors: Abdolamir Landi, Michael Houghton, D. Lorne Tyrrell, Tim Lankisch, Tobias Weismueller, Michael Manns
  • Methods and Compositions for Diagnosis of Inflammatory Liver Disease
    Publication number: 20170153251
    Abstract: The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
    Type: Application
    Filed: November 21, 2016
    Publication date: June 1, 2017
    Inventors: Abdolamir Landi, Michael Houghton, D. Lorne Tyrrell, Tim Lankisch, Tobias Weismueller, Michael Manns
  • Methods and compositions for diagnosis of inflammatory liver disease
    Patent number: 9535071
    Abstract: The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: January 3, 2017
    Assignees: The Governors of the University of Alberta, Medizinische Hochschule Hannover
    Inventors: Abdolamir Landi, Michael Houghton, D. Lorne Tyrrell, Tim Lankisch, Tobias Weismueller, Michael Manns
  • Methods and Compositions for Diagnosis of Inflammatory Liver Disease
    Publication number: 20150219664
    Abstract: The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
    Type: Application
    Filed: September 6, 2013
    Publication date: August 6, 2015
    Applicant: Medizinische Hochschule Hannover
    Inventors: Abdolamir Landi, Michael Houghton, D. Lorne Tyrrell, Tobias Weismueller, Michael Manns